Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-014233
Filing Date
2025-02-14
Accepted
2025-02-14 16:41:39
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10825
  Complete submission text file 0001104659-25-014233.txt   12556
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Subject) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92596 | Film No.: 25630076
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 767 THIRD AVENUE, 17TH FLOOR NEW YORK NY 10017
Business Address 767 THIRD AVENUE, 17TH FLOOR NEW YORK NY 10017 646-970-2123
Paradigm Biocapital Advisors LP (Filed by) CIK: 0001855655 (see all company filings)

EIN.: 851451055 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A